- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Akero Therapeutics is a biotechnology business based in the US. Akero Therapeutics shares (AKRO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $29.34 – an increase of 1.56% over the previous week. Akero Therapeutics employs 60 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Akero Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Akero Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – AKRO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Akero Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Akero Therapeutics stock price (NASDAQ: AKRO)
Use our graph to track the performance of AKRO stocks over time.Akero Therapeutics shares at a glance
Information last updated 2024-12-19.
| Latest market close | $29.34 |
|---|---|
| 52-week range | $15.32 - $37.00 |
| 50-day moving average | $30.83 |
| 200-day moving average | $25.94 |
| Wall St. target price | $48.27 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.78 |
Is it a good time to buy Akero Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Akero Therapeutics price performance over time
Historical closes compared with the close of $29.34 from 2024-12-20
| 1 week (2024-12-13) | 1.56% |
|---|---|
| 1 month (2024-11-22) | -10.36% |
| 3 months (2024-09-20) | 4.49% |
| 6 months (2024-06-21) | 26.47% |
| 1 year (2023-12-22) | 27.12% |
|---|---|
| 2 years (2022-12-22) | -38.73% |
| 3 years (2021-12-22) | 36.72% |
| 5 years (2019-12-20) | 43.54% |
Akero Therapeutics financials
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -23.17% |
| Return on equity TTM | -35.9% |
| Profit margin | 0% |
| Book value | $10.61 |
| Market Capitalization | $2 billion |
TTM: trailing 12 months
Akero Therapeutics share dividends
We're not expecting Akero Therapeutics to pay a dividend over the next 12 months.
Akero Therapeutics share price volatility
Over the last 12 months, Akero Therapeutics's shares have ranged in value from as little as $15.32 up to $37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akero Therapeutics's is -0.26. This would suggest that Akero Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Akero Therapeutics has bucked the trend.
Akero Therapeutics overview
Akero Therapeutics, Inc. , together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc.
Frequently asked questions
What percentage of Akero Therapeutics is owned by insiders or institutions?Currently 5.305% of Akero Therapeutics shares are held by insiders and 105.357% by institutions. How many people work for Akero Therapeutics?
Latest data suggests 60 work at Akero Therapeutics. When does the fiscal year end for Akero Therapeutics?
Akero Therapeutics's fiscal year ends in December. Where is Akero Therapeutics based?
Akero Therapeutics's address is: 601 Gateway Boulevard, South San Francisco, CA, United States, 94080 What is Akero Therapeutics's ISIN number?
Akero Therapeutics's international securities identification number is: US00973Y1082 What is Akero Therapeutics's CUSIP number?
Akero Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00973Y108
More resources on Finder
More guides on Finder
-
How to buy Merck-and-Company stock (MRK)
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
-
How to buy Eli Lilly and Company stock (LLY)
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
-
How to buy Intuitive Surgical stock (ISRG)
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
-
How to buy Vertex Pharmaceuticals stock (VRTX)
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
-
How to buy McKesson Corporation stock (MCK)
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
-
How to buy UnitedHealth Group Incorporated stock (UNH)
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
-
How to buy Amgen stock (AMGN)
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
-
How to buy Abbott Laboratories stock (ABT)
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
-
How to buy Pfizer stock (PFE)
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
-
How to buy Johnson & Johnson stock (JNJ)
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Ask a question